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Abstract
Background: Landmark clinical trials have led to optimal treatment recommendations for patients with diabetes. Whether
optimal treatment is actually delivered in practice is even more important than the efficacy of the drugs tested in trials. To
this end, treatment quality indicators have been developed and tested against intermediate outcomes. No studies have
tested whether these treatment quality indicators also predict hard patient outcomes.
Methods: A cohort study was conducted using data collected from .10.000 diabetes patients in the Groningen Initiative to
Analyze Type 2 Treatment (GIANTT) database and Dutch Hospital Data register. Included quality indicators measured
glucose-, lipid-, blood pressure- and albuminuria-lowering treatment status and treatment intensification. Hard patient
outcome was the composite of cardiovascular events and all-cause death. Associations were tested using Cox regression
adjusting for confounding, reporting hazard ratios (HR) with 95% confidence intervals.
Results: Lipid and albuminuria treatment status, but not blood pressure lowering treatment status, were associated with
the composite outcome (HR= 0.77, 0.67–0.88; HR = 0.75, 0.59–0.94). Glucose lowering treatment status was associated with
the composite outcome only in patients with an elevated HbA1c level (HR= 0.72, 0.56–0.93). Treatment intensification with
glucose-lowering but not with lipid-, blood pressure- and albuminuria-lowering drugs was associated with the outcome
(HR= 0.73, 0.60–0.89).
Conclusion: Treatment quality indicators measuring lipid- and albuminuria-lowering treatment status are valid quality
measures, since they predict a lower risk of cardiovascular events and mortality in patients with diabetes. The quality
indicators for glucose-lowering treatment should only be used for restricted populations with elevated HbA1c levels.
Intriguingly, the tested indicators for blood pressure-lowering treatment did not predict patient outcomes. These results
question whether all treatment indicators are valid measures to judge quality of health care and its economics.
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Introduction
Patients with type 2 diabetes are at high risk for cardiovascular
morbidity and mortality, and often require treatment with drugs.
Treatment is aimed at reducing risk factors, such as high glucose,
blood pressure and lipid levels, with the ultimate goal to reduce
morbidity and mortality. A novel drug therapy showing a 15–25%
relative risk reduction in hard outcomes is considered to be a large
success [1–4]. Such evidence-based therapies are usually integrat-
ed in guidelines which define optimal treatment. However,
guideline implementation is difficult, and 10 to 55% of patients
with diabetes and elevated risk factors levels are not adequately
treated [5],[6]. Improvement of treatment in clinical practice thus
has the potential of a large reduction in morbidity and mortality.
The quality of treatment is as important as the drugs being
prescribed, but there is lack of knowledge on how best to measure
treatment quality. Therefore, valid treatment quality indicators are
needed that can be implemented in clinical practice and reflect
treatment effects.
Several treatment quality indicators for cardiovascular risk
management have been proposed by quality improvement
organizations [7–9]. They measure the percentage of patients
with a certain treatment status, that is, patients receiving or not
receiving a specific medication at one point in time. As alternative,
clinical action indicators have been proposed [10–12], which
measure the percentage of patients in whom treatment is started or
intensified when indicated. Before implementation, it is important
to know whether treatment as measured by means of the quality
indicators is predictive of better patient outcomes. Although there
is an extensive evidence from clinical trials that better treatment
leads to better outcomes [1–4], poorly defined treatment quality
indicators or indicators using wrong assumptions are not likely to
result in better patient outcomes. Such indicators may inade-
quately capture the indication for treatment, or be too simplistic to
reflect treatment quality over time.
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Previous studies tested whether treatment quality indicators are
predictive of better intermediate outcomes in patients with
diabetes. It was found that indicators measuring glucose or
cholesterol lowering treatment status showed predictive value on
intermediate outcomes, that is, better glycemic and cholesterol
control [5],[6],[12],[13]. The indicators measuring whether
treatment was started or intensified in uncontrolled patients,
showed predictive value for glycemic, as well as blood pressure and
cholesterol control. Although these intermediate outcomes are
considered to be predictors of cardiovascular events [14–17], the
direct relationship between treatment quality indicators and hard
outcomes is unknown [18].
The aim of this study is to test which treatment quality
indicators are predictive of a lower risk of cardiovascular outcomes
in patients with type 2 diabetes. We conducted a cohort study
measuring the treatment quality in primary care using various
indicators and assessing their relation to patient outcomes in a
follow-up period of three years. The indicators predictive of better
hard outcomes were identified.
Methods
Patients who had been diagnosed with type 2 diabetes before 1
January 2007 were selected from the GIANTT (Groningen
Initiative to Analyze Type 2 Diabetes) database [19]. This
regional longitudinal database contains anonymized data extract-
ed from electronic medical records (EMR) of type 2 diabetes
patients from the north of the Netherlands who are managed in
primary care. These records include prescription data, medical
history, routine laboratory test results and physical examinations.
Medical history data includes diagnoses, which are documented in
the medical records by means of the International Classification of
Primary Care (ICPC) [20] or short text descriptions which were
manually coded in GIANTT.
Data on patient cardiovascular events and mortality were
collected from the Dutch Hospital Data register and municipality
register provided by the Central Bureau of Statistics in the
Netherlands [21]. These data include patients discharge diagnoses
that are coded according to the International Classification of
Diseases-9-Clinical Modification, hospital procedure codes that
are coded according to the Classification of Medical Procedures
developed by the Central Administration of Procedures in the
Netherlands, and mortality information.
Quality indicators
We selected a range of commonly used and recommended
quality indicators for treatment of cardiovascular risk factors in
patients with diabetes from national indicator sets and a previous
review study [7–10]. The complete list of the fourteen included
quality indicators and their definitions is presented in Table 1. The
treatment quality was measured in the year 2007.
The indicators of current treatment status measured whether (1)
patients with diabetes are treated with glucose- or lipid-lowering
drugs, (2) patients with diabetes and elevated levels of HbA1c,
systolic blood pressure (SBP) or albumin:creatinine ratio (ACR)
are treated with glucose-, blood pressure- or albuminuria-lowering
drugs. A patient was considered as being treated when a
prescription was recorded within the last three months of the
measurement year, since a single prescription can be issued for a
maximum period of 3 months in The Netherlands.
The indicators of treatment intensification measured whether
patients with diabetes and an elevated risk factor level received a
start or intensification of pharmacotherapy. According to the
Dutch guidelines in 2007, such treatment intensification was
recommended for patients with levels of HbA1c.7% (53 mmol/
mol); low density lipoprotein cholesterol (LDL-C).2.5 mmol/l;
SBP.=140 mm Hg; and ACR.=2.5 mg/mmol (males)
and.=3.5 mg/mmol (females) [22]. Since treatment quality
might be more at stake at higher thresholds, we also included
treatment indicators focusing on patients with more elevated
risk factor levels of HbA1c.8.5% (69 mmol/mol), LDL-C.
3.5 mmol/l, and SBP.=160 mmHg [23],[24]. Moreover, since
doctors may wait for a confirmation blood pressure reading before
intensifying treatment, we included the indicators measuring
treatment intensification after two sequentially elevated blood
pressure levels within 150 days [10].
A patient was considered as receiving treatment intensification
when a new drug class was started or added, or a dosage was
increased within a period of 180 days after the first elevated risk
factor level in 2007. Switches between drugs were not included as
intensification. The included drug classes are presented in Table
S1.
Patients on maximum treatment were excluded from the
intensification indicators, since there is no room for further
intensification of drug treatment in primary care setting. We
defined maximum treatment according to the Dutch guideline for
primary care. The following treatment was considered as
maximum treatment: for glucose lowering treatment, the use of
insulin; for lipid lowering treatment, the use of one or more drugs
at maximum maintenance dosage; for blood pressure lowering
treatment, the use of 3 or more drugs classes at maximum
maintenance dosage; for albuminuria lowering treatment, pre-
scribing of either angiotensin-converting enzyme inhibitor (ACE-i)
or an angiotensin-II-receptor blockers (ARB) at maximum dosage.
Dosage recommendations were obtained from the Dutch Phar-
macotherapy Compendium [25].
Outcomes
The outcome of this study was a composite of cardiovascular
events, including myocardial infarction, stroke, transient ischemic
attack, coronary revascularization procedures, peripheral vascular
complications, and all-cause death. The complete list of included
events is presented in Table S2.
Statistical analysis
Using standardized differences, we compared baseline charac-
teristics of patients receiving with those not receiving treatment
according to a quality indicator. Follow-up time and diabetes
duration are presented as median with interquartile ranges (IQR).
Diabetes duration is categorized to ,3, 3–10, and .10 years for
further analyses, since recently diagnosed patients are assumed to
be different from those having diabetes for many years with regard
to treatment decision. This difference is not expected to be
proportional to diabetes duration. Other continuous variables are
presented as means with standard deviations (SD). We used Cox
Proportional Hazards regression to test the association between
each of the included quality indicators and the outcomes. The
provision of treatment or treatment intensification according to the
quality indicator was defined as binary independent variable at
patient level. Outcome risk was measured from the index date to
the event date. For patients receiving treatment according to the
quality indicator, the index date was the date of the last
prescription or the date of treatment intensification in 2007. For
the control group, the index date was a randomly generated date
computed according to the observed distribution of treatment
prescription dates of patients with treatment or treatment
intensification in 2007. Patients who were lost due to changes in
place of residence in the year of quality measurement (2007) were
Treatment Quality in Diabetes and Outcomes
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excluded from the analysis. Patients who were lost due to changes
in place of residence during the follow-up period (2008–2010)
were censored. Patients with missing baseline risk factor test in
2007 were excluded from the analyses per indicator, since
treatment and treatment intensification were computed in relation
to a risk factor test.
We tested the proportional hazards assumption for each
covariate in all models by examining scatterplots of residuals
against hazard time, which revealed no violation of the
proportionality assumption.
Confounding
For each indicator, a crude model adjusting only for baseline
history of cardiovascular events, and a fully adjusted model
including other patient characteristics were built. Most impor-
tantly, this adjustment is needed to reduce confounding by
indication, that is, patients who are sicker are likely to be treated
more aggressively but may still have worse outcomes, leading to
negative associations. These patient characteristics are age,
gender, diabetes duration, baseline risk factor level, baseline
treatment status (glucose-, blood pressure-, lipid-lowering drugs),
history of malignancies, and history of psychological disorders.
The complete list of baseline cardiovascular morbidity and
concomitant diseases is presented in Table S3.
Ethics statement
In The Netherlands, according to the Code of Conduct for the
use of data in Health Research (‘‘Gedragscode gezondheidson-
derzoek’’ approved in 2004 by the Dutch College for Protection of
Personal Data, taking into account Article 25 of the Dutch Act on
the Protection of Personal Data) no ethics committee approval was
required for this research using data from anonymous medical
records.
Results
A cohort of 10058 patients with type 2 diabetes was eligible for
this study, excluding 893 patients who were not identifiable in the
Dutch Hospital Data register and 74 patients for whom disease
duration was missing. Baseline patient characteristics are shown in
Table 2. Depending on the eligibility criteria, the number of
Table 1. Definitions of quality indicators.
Treatment quality indicators Baseline factor Definition of quality
HbA1c
Diabetes patients with HbA1c test who are treated with glucose
lowering drug(s)
First HbA1c test in 2007 Glucose lowering drug prescription within last 3
months of 2007
Diabetes patients with HbA1c .7% who are treated with glucose
lowering drug(s)
First HbA1c test in 2007 if value .7% Glucose lowering drug prescription within last 3
months of 2007
Diabetes patients with HbA1c .7% not on maximum treatment
receiving glucose lowering treatment intensification
First HbA1C test in 2007 if value .7% Glucose lowering drug start or dosage increase
within 180 days after baseline test
Diabetes patients with HbA1c .8.5% not on maximum treatment
receiving glucose lowering treatment intensification
First HbA1c test in 2007 if value .8.5% Glucose lowering drug start or dosage increase
within 180 days after baseline test
Low-density lipoprotein cholesterol (LDL-C)
Diabetes patients with LDL-C test who are treated with lipid
lowering drugs
First LDL-C test in 2007 Lipid lowering drug prescription within last 3
months of 2007
Diabetes patients with LDL-C .2.5 mmol/l not on maximum
treatment receiving lipid lowering treatment intensification
First LDL-C test in 2007 if
value .2.5 mmol/l
Lipid lowering drug start or dosage increase
within 180 days after baseline test
Diabetes patients with LDL-C .3.5 mmol/l not on maximum
treatment receiving lipid lowering treatment intensification
First LDL-C test in 2007 if
value .3.5 mmol/l
Lipid lowering drug start or dosage increase
within 180 days after baseline test
Systolic blood pressure (SBP)
Diabetes patients with SBP $140 mm Hg who are treated with
blood pressure lowering drug(s)
First SBP test in 2007 if
value $140 mm Hg
Blood pressure lowering drug prescription
within last 3 months of 2007
Diabetes patients with SBP $140 mm Hg not on maximum
treatment receiving blood pressure lowering treatment
intensification
First SBP test in 2007 if
value $140 mm Hg
Blood pressure lowering drug start or dosage
increase within 180 days after baseline test
Diabetes patients with SBP $160 mm Hg not on maximum
treatment receiving blood pressure lowering treatment
intensification
First SBP test in 2007 if
value $160 mm Hg
Blood pressure lowering drug start or dosage
increase within 180 days after baseline test
Diabetes patients with 2 sequential SBP $140 mm Hg receiving
blood pressure lowering treatment intensification
First SBP test in 2007 with
value $140 mm Hg
Blood pressure lowering drug start or dose
increase within 180 days after baseline test
Diabetes patients with 2 sequential SBP $160 mm Hg receiving
blood pressure lowering treatment intensification
First SBP test in 2007 with
value $160 mm Hg
Blood pressure lowering drug start or dose
increase within 180 days after baseline test
Albumin:creatinine ratio (ACR)
Diabetes patients with $2.5 mg/mmol (males) or
$3.5 mg/mmol (females) treated with ACE-inhibitors or
angiotensin receptor blocker (ARB)
First ACR test in 2007 if value
$2.5 mg/mmol (males) or $
3.5 mg/mmol (females)
ACE-i or ARB drug prescription within last 3
months of 2007
Patients with ACR $2.5 mg/mmol (males) or $3.5 mg/mmol
(females) receiving ACE-inhibitors or ARB treatment
intensification
First ACR test in 2007 if value $
2.5 mg/mmol (males) or $3.5 mg/mmol
(females)
ACE-i or ARB start or dosage increase within 180
days after baseline test
doi:10.1371/journal.pone.0078821.t001
Treatment Quality in Diabetes and Outcomes
PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e78821
patients included per indicator ranged from 401 to 8455 (Table 3).
The median follow-up ranged from 3.1 to 3.6 years across the
models, which tested the associations between the each of the
fourteen quality indicators and hard outcomes (mean of the
medians follow-up 3.3 years (IQR 3.1–3.5). Percentages of patients
who had a cardiovascular outcome during follow-up varied from
15.2% to 30.6% across the models. Baseline patients character-
istics per indicator are presented in Table S4. In general, patients
who received treatment for a specific risk factor were older, with a
longer diabetes duration, had more related comorbidity and
comedication. Patients with elevated risk factor levels receiving
treatment intensification, in turn, were generally younger, with a
shorter diabetes duration, less related comorbidity and comedica-
tion, and had a higher baseline risk factor level. The numbers of
patients receiving treatment according to quality indicators and
the number of events per indicator are presented in Table 3.
Generally, treatment levels were high, whereas treatment inten-
sification levels were low (Table 3).
Quality indicators measuring current treatment status
Being treated with lipid and albuminuria lowering drugs was
significantly associated with a lower risk of hard outcomes
(Figure 1). Being treated with glucose lowering drugs was
significantly associated with a lower risk of hard outcomes only
in patients with an elevated HbA1c level. Being treated with blood
pressure lowering drugs was not significantly associated with hard
outcomes.
Quality indicators measuring treatment intensification
when indicated
Treatment intensification with glucose lowering drugs was
significantly associated with a lower risk of hard outcomes
(Figure 1). In turn, treatment intensification with lipid-, blood
pressure- and albuminuria-lowering drugs was not significantly
associated with a risk of hard outcomes.
Discussion
This study shows that the quality indicators measuring current
treatment status with lipid- and albuminuria-lowering drugs
predicted a lower risk of hard cardiovascular outcomes in patients
with diabetes in general practice. For the indicators measuring
treatment intensification, only the one focusing on glucose
lowering treatment intensification predicted a lower risk of hard
outcomes. None of the quality indicators measuring blood pressure
lowering treatment or treatment intensification were predictive of
hard outcomes.
Quality indicators are increasingly used for measuring the
quality of diabetes care to improve providers performance and
patients health [23], e.g., in the Quality and Outcome Framework
in the United Kingdom [7]. To our knowledge, this is the first
longitudinal study assessing which treatment quality indicators for
patients with diabetes are predictive of hard outcomes in primary
care. Especially when indicators are used by policy makers for
public reporting or by insurance companies for rewarding
providers, it is essential to identify quality indicators that directly
reflect providers’ actions and lead to benefits in patient outcomes.
Due to bias in the indicator definition or inadequate assessment of
treatment quality not all of the quality indicators predict better
patient outcomes in practice. Alternatively, the evidence for some
treatments being beneficial may not be that straightforward when
translated to actual practice, where patients are often older and
have more comorbidity in comparison to the trial populations.
Whatever the reason, this study shows that such treatment quality
indicators should not be used as they are defined and measured
nowadays.
It is assumed that both treatment and treatment intensification
when indicated will lead to better intermediate outcomes and to a
lower risk of cardiovascular outcomes [16],[17]. Our composite
outcome included a range of macrovascular and microvascular
complications and all-cause death, which were proven to benefit
from adequate risk factor treatment [1–4]. The indicators
measuring current treatment status are relatively easy to calculate
Table 2. Patient characteristics at baseline (n = 10058).
Patient characteristics Number of patients with observation (%) Mean ± standard deviation
Age (years) 66.7612.2
Male gender 4805 (47.8)




HbA1c (%(mmol/mol)) 8602 (85.6) 6.9 (52)61.0 (8)
LDL-cholesterol (mmol/l) 6587 (65.5) 2.460.9
Systolic blood pressure (mm Hg) 8596 (85.5) 143.1620.8
Albumin:creatinine ratio (mg/mmol) 4699 (46.7) 5.0615.1
Treated with glucose lowering drugs 8450 (84.0)
Treated with lipid lowering drugs 7466 (74.2)
Treated with blood pressure lowering drugs 7587 (75.4)
History of cardiovascular morbidity 1970 (19.6)
History of malignancy 721 (7.2)
History of psychological comorbidity 379 (3.8)
*- median (25th and 75th percentiles).
doi:10.1371/journal.pone.0078821.t002
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using routinely collected data from clinical practice. They are
included in several national indicator sets for quality assessment
[7–9]. Previously, the lipid lowering treatment indicator showed
an association with intermediate outcomes in patients with
diabetes [6]. Our study adds to this knowledge by showing that
this indicator also predicts a lower risk of hard outcomes.
Apparently, assessing whether patients with diabetes are being
treated with lipid lowering drugs at one point in time is a good
measure of adequate treatment. Furthermore, the glucose
lowering treatment indicator was previously found to be only
predictive of better intermediate outcomes in a restricted
population of patients with an elevated HbA1c level [5]. In the
current study, we found the same need for restriction when looking
at hard outcomes. Since there is no need to prescribe glucose
lowering treatment to patients who are well-controlled on diet, the
eligible population for this treatment indicator should be restricted
to uncontrolled patients. An interesting finding of our study was
that the indicator measuring albuminuria lowering treatment
status was predictive of a lower risk of hard outcomes, where it
previously showed no association with albuminuria control [6].
This finding may reflect the fact that antihypertensive treatment
with drugs acting on renin-angiotensin-system is advised in
patients with increased albuminuria. These drugs appear to have
a specific cardiovascular protection beyond their effect on one
single risk factor [4]. The quality indicator of blood pressure
lowering treatment status was not predictive of hard outcomes.
Previously, it was found that such an indicator was also not
associated with blood pressure control [6]. These findings may
Table 3. Predictive value of quality indicators on a composite of cardiovascular events and all-cause death represents the hazard















Treated with glucose lowering drugs Yes 6754 (79,9%) 1225 0.93 (0.82; 1.05) 0.91 (0.80; 1.03)
No 1701 (20,1%) 320
Treated with glucose lowering drugs in patients with HbA1c
.7 (%)
Yes 2462 (91,2%) 497 0.66 (0.51; 0.85) 0.72 (0.56; 0.93)
No 238 (8,8%) 70
Treatment intensification in patients with HbA1c .7 (%) Yes 848 (34,5%) 135 0.65 (0.53; 0.79) 0.73 (0.60; 0.89)
No 1607 (65,5%) 386
Treatment intensification in patients with HbA1c .8.5 (%) Yes 145 (36,2%) 26 0.80 (0.50; 1.28) 0.75 (0.47; 1.23)
No 256 (63,8%) 56
Treated with lipid lowering drugs Yes 4360 (67,4%) 662 0.65 (0.58; 0.73) 0.77 (0.67; 0.88)
No 2111 (32,6%) 442
Treatment intensification in patients with LDL-C .2.5 (mmol/l) Yes 375 (16,7%) 59 0.84 (0.64; 1.11) 1.06 (0.80; 1.42)
No 1864 (83,3%) 343
Treatment intensification in patients with LDL-C .3.5 (mmol/l) Yes 184 (26,9%) 36 1.13 (0.76; 1.66) 1.43 (0.96; 2.13)
No 499 (73,1%) 87
Treated with blood pressure lowering drugs in patients
with SBP $140 (mmHg)
Yes 3915 (79,3%) 803 1.12 (0.95; 1.32) 1.07 (0.91; 1.27)
No 1022 (20,7%) 172
Treatment intensification in patients with SBP $140 (mmHg) Yes 1004 (20,6%) 216 1.05 (0.90; 1.22) 1.02 (0.88; 1.20)
No 3860 (79,4%) 795
Treatment intensification in patients with 2 sequential
SBP tests $140 (mmHg)
Yes 982 (23,7%) 210 1.05 (0.90; 1.23) 1.07 (0.91; 1.26)
No 3164 (76,3%) 647
Treatment intensification in patients with SBP $160 (mmHg) Yes 598 (30,7%) 140 0.98 (0.81; 1.20) 1.00 (0.82; 1.23)
No 1349 (69,3%) 324
Treatment intensification in patients with 2 sequential
SBP tests $160 (mmHg)
Yes 618 (40,1%) 146 0.98 (0.79; 1.20) 1.02 (0.83; 1.26)
No 925 (59,9%) 226
Treated with ACE-I or ARB in patients with ACR $2.5 (males)
or $3.5 (females) (mg/mmol)
Yes 762 (64,2%) 182 0.70 (0.56; 0.88) 0.75 (0.59; 0.94)
No 425 (35,8%) 130
Treatment intensification in patients with ACR $2.5 (males)
or $3.5 (females) (mg/mmol)
Yes 143 (15,1%) 31 0.77 (0.53; 1.13) 0.79 (0.54; 1.15)
No 806 (84,9%) 217
Bold text indicates significant hazards ratio (cox regression); * - adjusted for baseline morbidity; ** - adjusted for baseline morbidity and comorbidity, baseline related
risk factor level, baseline medications and individual patients characteristics (age, gender, duration of diabetes).
doi:10.1371/journal.pone.0078821.t003
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seem surprising since clinical trials showed beneficial effect of
treatment on blood pressure and cardiovascular outcomes
[3],[26]. Quality indicators measuring blood pressure treatment,
as they are defined, may be too simplistic. They do not account for
any heterogeneity in the patient population or indication for
treatment, and disregard intrapersonal blood pressure variability.
This could be partly solved by making more specific indicators
(e.g. for specific age groups). In addition, the lack of association
with hard outcomes may be the result of including patients without
further treatment intensification when their blood pressure
deteriorates. It has been shown in a simulation study that patients
with diabetes and hypertension may need many intensifications to
keep their blood pressure level under control [27].
The alternative indicators for treatment quality in our study
measured whether patients with diabetes and an elevated risk
factor level received treatment intensification. We found that only
the indicator measuring glucose lowering treatment intensification
showed predictive value on a lower risk of hard outcomes.
Previously, it was shown that this indicator was predictive of better
intermediate outcome of glycemic control [5],[12]. Moreover, the
indicator measuring treatment intensification with lipid lowering
drugs previously also showed a predictive association with better
cholesterol control. It was somewhat unexpected that only the
intensification indicator for glucose lowering treatment was
predictive of a lower risk of hard outcomes, since glycemic control
appears to have less impact on cardiovascular outcomes compar-
ing with blood pressure and cholesterol control [1],[16]. One
could argue that unmeasured confounding may explain the
association between glucose lowering treatment intensification
and hard outcomes. That is, that sicker patients with more
comorbidity, who will have poorer outcomes, may be less
aggressively treated for their diabetes. However, in a previous
study we found no evidence that comorbid conditions decrease the
likelihood to intensify medication treatment in patients with
diabetes [28]. Moreover, the absence of associations between the
indicators measuring lipid- and blood pressure-lowering treatment
intensification and hard outcomes also makes this explanation less
likely. An alternative explanation for the difference in associations
for these indicators may be that they do not adequately reflect
fluctuations in the quality of drug treatment over time. In the long
run, patients may deteriorate if further intensification is not
prescribed when needed. Health care providers’ behavior is not
necessarily consistent regarding treatment intensification over
time. Previously, it was shown that providers are more prone to
intensify glucose lowering than blood pressure- or cholesterol-
lowering treatment [29]. For blood pressure lowering treatment an
alternative indicator has been suggested, which assesses the
number of treatment intensifications longitudinally in relation to
the number of occasions where the blood pressure level was
elevated [30]. This indicator showed good prediction of interme-
diate outcomes [31], but has not yet been tested against hard
outcomes.
Figure 1. Predictive value of quality indicators on a composite of cardiovascular events and all-cause death. Legend: The predictive
value is represented as the hazard of event occurrence in patients treated as defined by the quality indicator in comparison to those not treated as
such after adjusting on patients characteristics, that is age, gender, duration of diabetes, baseline risk factor level, baseline treatment status (glucose-,
blood pressure-, lipid-lowering drugs), history of malignancies, and history of psychological disorders. CT – current treatment; TI – treatment
intensification; GLD – glucose-lowering drugs; LLD – lipid-lowering drugs.
doi:10.1371/journal.pone.0078821.g001
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Finally, non-adherence to treatment may also explain a lack of
association between quality indicators measuring treatment
intensification and hard outcomes. Non-adherence is common
among patients with diabetes and associated with a higher risk of
cardiovascular outcomes [32]. When clinicians are not aware of
the non-adherence, they are likely to intensify treatment in such
patients. This phenomenon has been observed for lipid- and
blood-pressure lowering treatment but not for glucose lowering
treatment [32–34]. On the other hand, a small observational study
using alternative indicator measuring treatment intensification
showed an improvement in blood pressure control regardless of
the patient’s adherence level [35].
Strengths and limitations
This study was conducted in a large cohort of patients with
diabetes from a primary care setting in the north of the
Netherlands. We lost 8% of patients who could not be linked to
the hospital data because they changed their place of residence.
The population of our cohort consists mainly of individuals of
West-European origin, which may influence a risk of vascular
events occurrence [36]. Observational studies are susceptible to a
number of biases. For quality indicators, it is assumed that all
eligible patients have an indication for treatment or treatment
intensification. However, patients who are more likely to get the
outcome may also be more likely to get treatment, which could
lead to unexpected associations between the indicator and the
outcome. Therefore, we adjusted the tested associations for
baseline treatment status, morbidity and other patients character-
istics which may be possible confounders. Our adjustment on
baseline morbidity, however, was based on morbidity history data
from primary care records, which might not be complete [37]. We
tried to minimize incompleteness by enriching the diagnoses data
by manually coding text descriptions. Although we adjusted the
tested association for possible confounders, there may be
unmeasured confounding, partly related to patient behavior. We
did not adjust the tested associations for non-adherence or lifestyle,
which may lead to underestimation of the associations between
indicators and outcomes. Another limitation of our study is that
the data on cardiovascular outcomes in 2010 was incomplete,
because one regional hospital did not provide data to the Dutch
Hospital Data register that year.
Conclusions
This study demonstrated that treatment quality indicators are
not always reliable instruments for measuring diabetes treatment
quality as observed in primary care. The quality indicators
measuring lipid- and albuminuria-lowering treatment status can
be considered for implementation into quality indicator sets, since
these indicators appear to result in less cardiovascular outcomes.
The indicator measuring glucose lowering treatment status should
be restricted to include only patients with an elevated HbA1c. The
indicators measuring blood pressure lowering treatment status
cannot be used as such, since they are not related to cardiovascular
outcomes. To measure quality of blood pressure lowering
treatment, the use of indicators assessing treatment over time
needs further exploration. Finally, indicators measuring treatment
intensification at one point of time may be helpful for quality
improvement initiatives, to show where action is needed, but they
do not reliably predict treatment quality over time. Since
treatment over time is not only associated with patients’ well-
being and disease burden, but also with health economics,
repeated measurement of treatment quality is needed for chronic
diseases.
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